Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus TOFACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus TOFACITINIB.
BARICITINIB vs TOFACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 and JAK3, thereby modulating the JAK-STAT signaling pathway to reduce cytokine production and immune cell activation.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
5 mg orally twice daily; extended-release formulation 11 mg orally once daily. For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. For ulcerative colitis, induction: 10 mg orally twice daily for 8 weeks, then maintenance 5 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTofacitinib + Digoxin
"Tofacitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateTofacitinib + Bendroflumethiazide
"Tofacitinib may increase the bradycardic activities of Bendroflumethiazide."
Clinical Note
moderateTofacitinib + Sulfisoxazole
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Terminal half-life approximately 3.3 hours in healthy volunteers. In patients with rheumatoid arthritis, effective half-life ~3-6 hours due to reversible binding to JAK enzymes. No significant accumulation at steady state.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Primarily renal (70%) with 30% excreted unchanged in urine. Fecal elimination accounts for 20% (<1% unchanged). Minor biliary excretion.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor
"The metabolism of Sulfisoxazole can be decreased when combined with Tofacitinib."